Casdin Capital Portfolio

Casdin Capital 13F filer (CIK 0001534261).

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q1 2021 · 48 positions · Total reported value $3.36B · Top-10 concentration 63.1% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 26.1% · 6 new · 3 cut · 3 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 99.9% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +47.2% · vs SPY +32.4% · Prev Value $1.32B — last quarter positions weighted by this quarter price moves · ranking

In its Q1 2021 13F filing, Casdin Capital disclosed 48 equity positions with a combined reported value of $3.36B. The filing implies a focused portfolio: its ten largest positions account for 63.1% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q1 2021 were NVTAQ ($466.30M), EXAS ($311.02M), FATE ($280.33M). By sector, the heaviest allocations are Health Care 53.1%, Industrials 8.7%. Versus the prior quarter, allocation shifted toward Other (+1.8pp), Industrials (+1.1pp) and away from Health Care (-2.9pp).

Versus the prior quarter, Casdin Capital opened 6 new positions, trimmed 3 and fully exited 3, a turnover rate of 26.1% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q1 2021 were ORTX ($23.34M), DBTX ($13.02M), CLOV ($5.49M).

Of the 3 positions fully exited versus the prior quarter, the largest were BLUE ($39.59M), IOVA ($25.52M), AMRSQ ($12.35M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q1 2021)

  • ORTX ORCHARD THERAPEUTICS PLC · $23.34M
  • DBTX Decibel Therapeutics Inc · $13.02M
  • CLOV CLOVER HEALTH INVESTMENTS CO · $5.49M
  • SANA SANA BIOTECHNOLOGY INC · $2.01M

Fully Exited (vs previous quarter)

  • BLUE BLUEBIRD BIO INC · prev qtr: $39.59M
  • IOVA IOVANCE BIOTHERAPEUTICS INC COM · prev qtr: $25.52M
  • AMRSQ AMYRIS INC · prev qtr: $12.35M
  • BDTX BLACK DIAMOND THERAPEUTICS I · prev qtr: $9.28M
  • ABCL ABCELLERA BIOLOGICS INC · prev qtr: $8.05M
  • BMYRT BRISTOL-MYERS SQUIBB CO · prev qtr: $4.31M
  • CCCC C4 THERAPEUTICS INC · prev qtr: $1.32M

Insider Transactions (Form 4)

Latest Casdin Capital buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Casdin Capital is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 43 US equity positions with a combined value of $2.00B. HoldingsHub carries 43 quarters of its filings (Q4 2015–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-110894 (status: Approved), registered 2017-07-31
  • Regulatory AUM (Form ADV): $2.87B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 2 hedge funds

Portfolio Structure

  • 43 positions · $2.00B reported value (Q2 2026)
  • Top 10 holdings = 77.4% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 24.2%
  • Average position size: $46.46M

Sector Tilt

  • Health Care 94.2%
  • Industrials 5.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 9 added, 3 reduced, 3 exited
  • 25 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 53.1%
Other 38.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 12.20M $466.30M 13.89%
13.89%
Reduce
2 2.36M $311.02M 9.26%
9.26%
Add
3 3.40M $280.33M 8.35%
8.35%
Add
4 7.44M $267.84M 7.98%
7.98%
Hold
5 5.00M $166.55M 4.96%
4.96%
Hold
6 1.55M $150.71M 4.49%
4.49%
Hold
7 880.00K $124.25M 3.70%
3.70%
Add
8 1.00M $123.86M 3.69%
3.69%
Hold
9 3.38M $116.68M 3.48%
3.48%
Reduce
10 2.17M $111.80M 3.33%
3.33%
Reduce
11 4.33M $99.11M 2.95%
2.95%
Hold
12 1.61M $91.93M 2.74%
2.74%
Add
13 1.75M $88.63M 2.64%
2.64%
Add
14 1.84M $84.63M 2.52%
2.52%
Add
15 1.19M $81.25M 2.42%
2.42%
Hold
16 818.82K $65.54M 1.95%
1.95%
Add
17 150.00K $52.21M 1.55%
1.55%
Hold
18 1.15M $46.30M 1.38%
1.38%
Add
19 1.30M $45.89M 1.37%
1.37%
Add
20 1.61M $45.85M 1.37%
1.37%
Hold
21 995.35K $43.18M 1.29%
1.29%
Add
22 1.80M $42.10M 1.25%
1.25%
Add
23 550.00K $40.99M 1.22%
1.22%
Add
24 3.35M $39.62M 1.18%
1.18%
Hold
25 900.00K $36.67M 1.09%
1.09%
Add
26 1.65M $33.23M 0.99%
0.99%
Hold
27 266.43K $32.46M 0.97%
0.97%
Hold
28 190.00K $25.35M 0.76%
0.76%
Hold
29 3.22M $23.34M 0.69%
0.69%
New
30 847.15K $22.80M 0.68%
0.68%
Reduce
31 1.00M $22.36M 0.67%
0.67%
Add
32 2.21M $21.81M 0.65%
0.65%
Reduce
33 406.50K $19.71M 0.59%
0.59%
Hold
34 583.44K $17.08M 0.51%
0.51%
Hold
35 820.44K $16.66M 0.50%
0.50%
Hold
36 601.51K $14.74M 0.44%
0.44%
Hold
37 1.24M $14.62M 0.43%
0.43%
Hold
38 1.15M $13.02M 0.39%
0.39%
New
39 200.00K $10.05M 0.30%
0.30%
Hold
40 610.00K $9.47M 0.28%
0.28%
Add
41 150.00K $7.50M 0.22%
0.22%
Hold
42 75.00K $7.09M 0.21%
0.21%
Hold
43 550.00K $6.89M 0.20%
0.20%
Reduce
44 726.51K $5.49M 0.16%
0.16%
New
45 120.00K $4.66M 0.14%
0.14%
Hold
46 216.22K $2.85M 0.09%
0.09%
Hold
47 60.00K $2.01M 0.06%
0.06%
New
48 76.69K $1.16M 0.03%
0.03%
Hold

FAQ

What did Casdin Capital buy in 2021-Q1?

In its 2021-Q1 13F filing, Casdin Capital reported 48 equity positions worth $3.36B in aggregate; its largest disclosed positions were NVTAQ ($466.30M), EXAS ($311.02M), FATE ($280.33M).

How large is Casdin Capital's portfolio?

Casdin Capital reported $3.36B of long equity holdings across 48 positions as of 2021-Q1. Top-10 holdings account for 63.1% of reported value.

What is Casdin Capital's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/casdin/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →